March 26, 2018 Amendment No. 4 to Amended and Restated Early Access Agreement with Impatients N.V

AMENDMENT NO. 4 TO

EARLY ACCESS AGREEMENT

This fourth Amendment to the Early Access Agreement (the “Agreement”) dated 20^th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 26 March 2018 (the “Amendment No. 4 Effective Date”).

RECITALS

WHEREAS, HEMISPHERX and IMPATIENTS are Parties to the Agreement for HEMISPHERX’S Product, Ampligen (rintatolimod);

WHEREAS, the Agreement has been amended on 13 December 2016, 28 June 2017 and 14 February 2018;

WHEREAS, the Parties wish to further amend the Agreement to establish that the Field for Canada shall not be limited to Pancreatic Cancer, as set forth below;

NOW, THEREFORE, the Parties hereby agree as follows:

Definitions and References. Except as set forth herein, capitalized terms not otherwise defined or amended in the Amendment shall have the meaning ascribed to them in the Agreement. References to Articles or Sections are the same with all of their subparts as they appear in the Agreement.

IN WITNESS WHEREOF, the respective Parties hereto have duly executed this Amendment as of the Amendment No. 4 Effective Date above. The persons executing this Amendment represent and warrant that they have the full power and authority to enter into this Amendment on behalf of the persons or entities for whom they are signing.